Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Osteopore Ltd. ( (AU:OSX) ) has shared an announcement.
Osteopore Limited has drawn down an additional A$250,000 sub-tranche (ST03) from Tranche 2 of its 4.0% redeemable convertible notes facility with Advance Opportunities Fund and Advance Opportunities Fund I, under a broader A$20 million program structured in four A$5 million tranches. This latest subscription, following earlier drawdowns from Tranche 1 and Tranche 2 in February, provides further funding for the company’s ordinary operations and future projects, supporting its growth objectives while adding to its mix of debt-like, potentially equity-convertible financing and signalling continued backing from its institutional investors.
The most recent analyst rating on (AU:OSX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. It develops patented scaffold implants that use naturally dissolving polymers to guide bone-forming cells, aiming to stimulate natural bone healing and reduce complications linked to permanent bone implants across multiple clinical segments.
Average Trading Volume: 31,878,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.5M
See more insights into OSX stock on TipRanks’ Stock Analysis page.